Uno, cento, mille diabeti - Parte seconda

1. Tornese G, Rubert L, Tonini G, Faleschini E. Uno, cento, mille diabeti - Parte prima. Diabete mellito di tipo 1 e 2. Medico e Bambino 2011;30(6):360-6. 2. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2011;34:S62-S69. 3. Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 1975;24(1):44-53. 4. Reisman D. Mild diabetes in children. Am J Med Sci 1916;151:40-5. 5. Graham G. Two cases of diabetes mellitus of an unusual type. Proc R Soc Med 1921;14:18-20. 6. Fajans SS, Conn JW. Tolbutamide-induced improvement in carbohydrate tolerance of young people with mild diabetes mellitus. Diabetes 1960;9:83-88. 7. Fajans SS. Treatment of chemical diabetes mellitus with sulfonylurea compounds. Metabolism 1973;22(2):373-6. 8. Tattersall RB. Mild familial diabetes with dominant inheritance. Q J Med 1974;43(170): 339-57. 9. Craig ME, Hattersley A, Donaghue KC. Definition, epidemiology and classification of diabetes in children and adolescents. Pediatric Diabetes 2009;10(Suppl 12):3-12. 10. Shields BM, Hicks S, Shepherd MH, et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010:53:2504-8. 11. Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ 2011;343:d 6044. 12. Schober E, Rami B, Grabert M, et al. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med 2009;26: 466-73. 13. Chiarelli F, Trotta D, Stoffers DA. MODY (maturity onset diabetes of the young): una nuova sfida per il medico. Agg Med 2001;25: 351-8. 14. McDonald TJ, Colclough K, Brown R, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from type 1 diabetes. Diabet Med 2011;28: 1028-33. 15. Lorini R, Klersy C, d’Annunzio G, et al. Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. Diabetes Care 2009;32(10):1864-6. 16. Prisco F, Iafusco D, Franzese A, Sulli N, Barbetti F. MODY 2 presenting as neonatal hyperglycaemia: a need to reshape the definition of “neonatal diabetes”? Diabetologia 2000; 43(10):1331-2. 17. Steele A, Shields BM, Shepherd M, Ellard S, Colclough K, Hattersley AT. Microvascular complication risk in patients with 50 years of moderate hyperglycaemia: are target ranges for glycaemic control appropriate? Diabet Med 2011;28:28. 18. Velho G, Blanche H, Vaxillaire M, et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 1997;40: 217-24. 19. Schober E, Rami B, Grabert M, et al. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med 2009;26: 466-73. 20. Temple IK, Gardner RJ, Mackay DJ, Barber JC, Robinson DO, Shield JP. Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. Diabetes 2000;49(8):1359-66. 21. Gardner RJ, Mackay DJ, Mungall AJ, et al. An imprinted locus associated with transient neonatal diabetes mellitus. Hum Mol Genet 2000;9(4):589-96. 22. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue KC. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatric Diabetes 2009;10(Suppl. 12):33-42. 23. Polak M, Shield J. Neonatal and very-early-onset diabetes mellitus. Semin Neonatol 2004; 9(1):59-65. 24. Greeley SAW, Tucker SE, Worrell HI, Skowron KB, Bell GI, Philipson LH. Update in neonatal diabetes. Curr Opin Endocrinol Diabetes Obes 2010;17:13-9. 25. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassiumchannel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350(18):1838-49. 26. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005;54(9): 2503-13. 27. Gloyn AL, Reimann F, Girard C, et al. Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet 2005;14(7):925-34. 28. Tonini G, Bizzarri C, Bonfanti R, et al. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (Kir6.2) gene. Diabetologia 2006;49 (9):2210-3. 29. Proks P, Arnold AL, Bruining J, et al. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet 2006; 15(11):1793-800. 30. Babenko AP, Polak M, Cave H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006; 355(5):456-66. 31. Nocerino V, Colombo C, Bonfanti R, et al. Mutations in IAPP and NEUROG3 genes are not a common cause of permanent neonatal/infancy/childhood-onset diabetes. Diabet Med 2009;26(6):660-1. 32. Russo L, Iafusco D, Brescianini S, et al. Permanent diabetes during the first year of life: multiple gene screening in 54 patients. Diabetologia 2011;54(7):1693-701. 33. Colombo C, Porzio O, Liu M, et al. Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus. J Clin Invest 2008;118(6):2148-56. 34. Senée V, Vattem KM, Delépine M, et al. Wolcott-Rallison Syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity. Diabetes 2004;53(7):1876-83. 35. Sabbah E, Savola K, Kulmala P, et al. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed Type 1 diabetes. J Clin Endocrinol Metab 1999;84:1534-9. 36. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993;42(2):359-62. 37. Zimmet PZ. The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography. Diabetes Care 1995;18 (7):1050-64. 38. Lohmann T, Nietzschmann U, Kiess W. “Lady-like”: is there a latent autoimmune diabetes in the young? Diabetes Care 2000;23 (11):1707-8. 39. Yki-Jarvinen H. Acute and chronic effects of hyperglycaemia on glucose metabolism. Implications for the development of new therapies. Diabet Med 1997;14(Suppl. 3):S32-S37. 40. Liu LL, Lawrence JM, Davis C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes 2010;11:4-11. 41. Becker DJ, Libman IM, Pietropaolo M. Changing phenotype of IDDM: is it type 1 or type 2? Pediatr Res 2001;49:93A. 42. Libman IM, Becker DJ. Coexistence of type 1 and type 2 diabetes mellitus: “double” diabetes? Pediatr Diabetes 2003;4(2):110-3. 43. Palmer JP, Hirsch IB. What’s in a name. Latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care 2003;26(2):536-8. 44. Vadacca M, et al. Gender differences and the metabolic syndrome in patients with type 2 diabetes with or without autoantibodies to glutamic acid decarboxilase (GAD). American Diabetes Association 67th Annual Scientific Sessions, 9-13 June 2006, Washington, DC, USA (Abstract Number: 1204-P). 45. Pozzilli P, Buzzetti R. A new expression of diabetes: double diabetes. Trends Endocrinol Metab 2007;18(2):52-7. 46. Pozzilli P, Guglielmi C, Caprio S, Buzzetti R. Obesity, Autoimmunity, and Double Diabetes in Youth. Diabetes Care 2011;34(S2):S166-S170. 47. Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. Diabetologia 2001;44 (7):914-22. 48. Wilkin TJ. The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. Int J Obes (Lond) 2009;33:716-26. 49. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005; 48(6):1038-50. 50. Broosk-Worrell BM, Greenbaum CJ, Palmer JP, Pihoker C. Autoimmunity to islet proteins in children diagnosed with new-onset diabetes. J Clin Endocrinol Metab 2004;89 (5):2222-7. 51. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 2003;26(1):138-43. 52. Reardon W, Ross RJ, Sweeney MG, et al. Diabetes mellitus associated with a pathogenic point mutation in mitochondrial DNA. Lancet 1992;340:1376-9. 53. van den Ouweland JM, Lemkes HH, Ruitenbeek W, et al. Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet 1992;1:368-71. 54. O’Riordan SMP, Robinson PD, Donaghue KC, Moran A. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 2009;10(Suppl 12):43-50. 55. Lanngs S, Thorsteinsson B, Pociot F, et al. Diabetes mellitus in cystic fibrosis: genetic and immunological markers. Acta Paediatr Scand 1993;82(2):150-4. 56. O’Riordan SGA, Ennis S, George S, et al. Genetics of cystic fibrosis related diabetes and non diabetes. Horm Res 2007;68(Suppl.1):44-69. 57. Hardin DS, Leblanc A, Marshall G, Seilheimer DK. Mechanisms of insulin resistance in cystic fibrosis. Am J Physiol Endocrinol Metab 2001;281:E1022-8. 58. Bismuth E, Laborde K, Taupin P, et al. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr 2008;152:540-5. 59. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005;146:681-7. 60. O’Riordan SM, George S, Hoey H, Costigan C. Continuous glucose monitoring enhances the detection of cystic fibrosis related diabetes in children with cystic fibrosis. Diabetologia 2007;50(Suppl. 1):S1-S538. 61. Marchetti F, Tornese G, Faleschini E, Poli F. Diagnosis of diabetes. What about cystic fibrosis? BMJ 2009;339:b5644. 62. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002;35:246-59. 63. Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999;68:396-402. 64. Pui CH, Burghen GA, Bowman WP, Aur RJ. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr 1981;99:46-50. 65. Al Urzi A, Stablein DM, Cohn A. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001;72: 1020-4. 66. Maes BD, Kuypers D, Messianen T, et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001;72:1655-61.